NCT04845191View on ClinicalTrials.gov

COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

December 31, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 14, 2021

Conditions

Covid19

Interventions

BIOLOGICAL

hAd5-S-Fusion+N-ETSD vaccine

hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.